Attenuation of collagen-induced arthritis by orally available imidazoline-based NF-κB inhibitors.
The pathogenesis of rheumatoid arthritis is mainly driven by NF-κB-mediated production of cytokines, such as TNF-α. We report herein that the orally available imidazoline-based NF-κB inhibitor, TCH-013, was found to significantly reduce TNF-α signaling and attenuate collagen antibody induced arthritis in BALB/c mice.
Department of Chemistry, Michigan State University, East Lansing, MI, USA.
Theresa A
TA
Lansdell
Sandra
S
O'Reilly
Tracey
T
Woolliscroft
Lauren M
LM
Azevedo
Daljinder K
DK
Kahlon
Stacy
S
Hovde
J Justin
JJ
McCormick
R William
RW
Henry
Joseph A
JA
Cornicelli
Jetze J
JJ
Tepe
D000284:Administration, Oral; D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology; D048288:Imidazolines / Q000008:administration & dosage / Q000138:chemical synthesis / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000276:immunology
D048288:Imidazolines; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha